GASTRORETENTIVE DRUG DELIVERY SYSTEM OF LEVO-SALBUTAMOL SULPHATE: FORMULATION AND IN VITRO EVALUATION
Abstract
In order to prepare the sustained release tablet with levo-salbutamol sulphate we have used these excipients methylcellulose, PVPK30, magnesium stearate, talc, isopropyl alcohol, microcrystalline cellulose, lactose, HPMCK100, HPMCK4M. Here our approach was for making the sustained released matrix tablet by two ways, one is to make the tablet granules floating and the second one is by retarding the release of the levo-salbutamol sulphate from the matrix. We have already discussed the relationship with delaying the gastric transit time and the active drug absorption, if the tablet granules are floating in our introduction part. Since the above mentioned excipients are floating in nature so formulations with those excipients are supposed to be floating. We also showed a list of excipients those are used in the preparation of floating tablets. Now the second observation which was the release rate, among the three different formulations (mentioned in the introduction) we found different types of release. Since our objective is to prepare a sustained released tablet which will give a prolong release time, in that prospect two among the three formulations were disqualified (though we have not done the kinetic study). We observed desired effect in the formulation-2 during the preparation of experiment.
Keywords:
Gastroretentive, Levo-salbutamol sulphate, BuoyancyDOI
https://doi.org/10.25004/IJPSDR.2016.080204References
2. Ahrens RC, Smith GD. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 1984; 4:105-121.
3. Swarbrick J, Boylon JC. Encyclopedia of Pharmaceutical Technology, 2nd ed, Vol 1, Marcel Dekker Inc, NewYork, 2002, pp. 896.
4. Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur J Clin Pharmacol. 1987; 32:631-634.
5. Pacifici GM, Giulianetti B, Quilici MC. Salbutamol sulphate in the human liver and duodenal mucosa: interindividual variability. Xenobiotica. 1997; 27:279-286.
6. Amperiadou A, Georgarakis M. Controlled release salbutamol sulphate microcapsules prepared by emulsion solvent-evaporation technique and study on the release affected parameters. Int J Pharm. 1995; 115:1-8.
7. Fishwick D, Bradshaw L, Macdonald C. Cumulative single-dose design to assess the bronchodilator effects of beta2- agonists in individuals with asthma. Am J Resp Crit Med. 2001; 163:474-477.
8. Crescioli S, Dal CA, Maestrelli P. Controlled release theophylline inhibits early morning airway obstruction and hyper responsiveness in asthmatic subjects. Ann Allergy Asthma Immunol. 1996; 77:106-110.
9. Villafuerte RL, Quirino BT, Jimenez MI. Sustained delivery of captopril from floating matrix tablets. Int J Pharm. 2008; 362:37-43.
10. Rouge N, Buri P, Doelkar E. Drug absorption sites in the gastrointestinal tract and dosage for site-specific delivery. Int J Pharm. 1996; 136: 117-139.
11. Umamaheshwari RB, Jain S, Bhadra D. Floating microspheres bearing acetohyxamic acid for the treatment of Helicobactor pylori. J Pharm Pharmacol. 2003; 55:1607-1613.
12. Jain SK, Awasthi AM, Jain NK. Calcium silicate based microspheres of repiglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J Control Rel. 2005; 107:300-309.
13. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech. 2004; 5(2):34.
14. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel. 2000; 63:235-259.
15. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003; 160-66.
Published
Abstract Display: 333 
PDF Downloads: 432 
